...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Zenith to present at Biotech Showcase in January

Also, Zenith (and Resverlogix) are both on the schedule for 30 minute CEO presentations at the BIO CEO and Investor Conference in New York, February 13-14. Thanks to JK on the Stockhouse board for posting about this.

https://www.bio.org/events/bio-ceo-investor-conference

BearDownAZ

Share
New Message
Please login to post a reply